Signifier Medical Technologies, based in Boston, announces the publication of a study titled “Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea” in The International Journal of Technology Assessment in Health Care. Led by Drs. Shan Liu and Jan Pietzsch, the research explores the viability of using neuromuscular electrical stimulation (NMES) as a treatment for mild obstructive sleep apnea (OSA).
Mild OSA affects millions in the US, often leading to a reduced quality of life and increased health risks. While continuous positive airway pressure (CPAP) therapy is the current standard treatment, its drawbacks prompt the search for alternatives. The study analyzes NMES’s cost-effectiveness compared to CPAP therapy and no treatment, showing promise as a cost-effective option for mild OSA.
Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier, emphasizes NMES’s potential to revolutionize mild OSA treatment. Unlike CPAP therapy, NMES, exemplified by Signifier’s eXciteOSA device, offers a non-invasive, daytime treatment option with high patient adherence rates.
Dr. Jan B. Pietzsch, the study’s senior author, highlights NMES’s significance in offering patients, clinicians, and payers cost-effective alternatives for mild OSA management. This study adds to ongoing efforts to improve sleep apnea treatment accessibility and effectiveness.
Signifier Medical Technologies, founded in 2015, is dedicated to developing non-invasive solutions to address sleep-disordered breathing root causes. Their eXciteOSA therapy, a daytime NMES treatment, aims to enhance patient health and healthcare experience while reducing costs.
